FeesSafety
Pluang+

Qualys rated 'Buy' with $202 target on strong revenue growth and cash flow despite share dip.

Company Fundamentals
13 Nov 2026, 20:53 WIB
Seeking Alpha
View Source
Bullish
Qualys rated 'Buy' with $202 target on strong revenue growth and cash flow despite share dip.

Qualys, a cloud security company, is rated 'Buy' with a $202 fair value due to strong billings growth and robust free cash flow. Partner channel revenue grew 23.6% year-over-year, now making up 55% of total revenue and driving all net growth as direct sales declined. Despite a 13.5% share price drop after earnings, Qualys posted 11% revenue growth and 14% billings growth, raising its full-year guidance. The company maintains operating margins in the mid-40% range, continues share buybacks supported by $808 million in cash, and has no debt, indicating strong financial health.

Qualys' strong billings growth and financial health provide context for readers following the company. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Nov 14, 2026 00:31 WIB: out of 150 priced stocks, 50 rose and 98 fell. Notable movers include AEHR at USD 57.02 with a 1-day change of -6.59% and Pluang order activity of 90% Sell / 10% Buy, ATOM at USD 2.71 down 6.55% with 100% Sell activity, and CRDO at USD 130.90 down 6.37% with 91% Buy activity and a typical hold time of 26 days.

More News

Organic Grower Summit 2026 adds live ag tech demos at Reservoir Farms for hands-on grower experience

Organic Grower Summit 2026 adds live ag tech demos at Reservoir Farms for hands-on grower experience

The Organic Grower Summit (OGS) 2026, held Dec. 2–3 in Monterey, California, introduces an exclusive offsite AGTech Reception & Field Demos at Reservoir Farms. Sponsored by John Deere, Western Growers Association, and Reservoir, this event offers gro...

Others
Bullish
58 minutes ago
New brain cancer drug data and trials spotlighted at Society for Neuro-Oncology meeting

New brain cancer drug data and trials spotlighted at Society for Neuro-Oncology meeting

At the 31st Annual Society for Neuro-Oncology meeting, biotech firms NeOnc, Nuvation Bio, Jazz Pharmaceuticals, and Cerenome presented new clinical data on brain cancer treatments. Highlights include NeOnc's NEO100 and NEO212 therapies advancing towa...

Market News
Bullish
1 hour ago
Subsea 7 wins $50M-$150M contract for deepwater project in US Gulf of Mexico starting 2028

Subsea 7 wins $50M-$150M contract for deepwater project in US Gulf of Mexico starting 2028

Subsea 7 has secured a sizeable contract from Kosmos Energy for the Tiberius Project in the US Gulf of Mexico, involving fabrication and installation of subsea infrastructure at about 2,200 meters depth. The work includes a 14-kilometer steel riser, ...

Market News
Bullish
1 hour ago
GlobeNewswire issues daily market update with no new financial news on Nov 13, 2026

GlobeNewswire issues daily market update with no new financial news on Nov 13, 2026

GlobeNewswire released its End of Day Message for November 13, 2026, confirming its role as an FCA-approved primary information provider. The update mainly reiterates its operational status and disclaimers, without reporting any new financial events ...

Market News
Neutral
1 hour ago
Space42 reports 11% revenue growth and 30% jump in normalized EBITDA for first nine months of 2026

Space42 reports 11% revenue growth and 30% jump in normalized EBITDA for first nine months of 2026

Space42, a UAE-based space technology company, announced strong financial results for the first nine months of 2026, with revenue up 11% to $404 million and normalized EBITDA rising 30% to $194 million. Growth was driven by its two main divisions: Sp...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App